Bristol Myers Squibb (CELG-RI) Exchange Rate Effect (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Exchange Rate Effect of -$48.0 million for Q1 2026, down 172.73% year-over-year from $66.0 million in Q1 2025, and down 1060.0% quarter-over-quarter from $5.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Exchange Rate Effect data on file, last reported at -$48.0 million in Q1 2026.
- Exchange Rate Effect for Q1 2026 came in at -$48.0 million, down 172.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.0 million (up 411.54% YoY), and the FY2025 annual result was $195.0 million, up 242.34% from the prior year.
- Exchange Rate Effect slipped to -$48.0 million in Q1 2026 per CELG-RI's latest filing, from $5.0 million in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $128.0 million in Q2 2025 and troughed at -$147.0 million in Q4 2024.
- A 5-year average of $1.3 million and a median of -$4.0 million in 2025 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect slumped 494.44% in 2022, then jumped 681.82% in 2025.
- A 5-year view of Exchange Rate Effect shows it stood at $95.0 million in 2022, then dropped by 17.89% to $78.0 million in 2023, then sank by 288.46% to -$147.0 million in 2024, then soared by 103.4% to $5.0 million in 2025, then sank by 1060.0% to -$48.0 million in 2026.
- Business Quant data shows CELG-RI's Exchange Rate Effect at -$48.0 million in Q1 2026, $5.0 million in Q4 2025, and -$4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FX Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.70 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 67.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -25.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -12.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -19.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -11.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 19.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -48.00 Mn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -48.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.00 Mn |
| Mar 31, 2026 | -48.00 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Mar 31, 2025 | 66.00 Mn |
| Mar 31, 2025 | 66.00 Mn |
| Dec 31, 2024 | -147.00 Mn |
| Dec 31, 2024 | -147.00 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Jun 30, 2024 | -22.00 Mn |
| Jun 30, 2024 | -22.00 Mn |
| Mar 31, 2024 | -45.00 Mn |
| Mar 31, 2024 | -45.00 Mn |
| Dec 31, 2023 | 78.00 Mn |
| Dec 31, 2023 | 78.00 Mn |